Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Credit agrmnt [a]
Quarterly results
Flexion Therapeutics Inc (FLXN) Create: Alert

All | News | Filings
Date FiledTypeDescription
11/29/2021 15-12B Form 15-12B - Securities registration termination [Section 12(b)]:
11/26/2021 EFFECT Form EFFECT - Notice of Effectiveness:
11/19/2021 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
11/19/2021 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
11/19/2021 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
11/19/2021 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
11/19/2021 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
11/19/2021 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
11/19/2021 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
11/19/2021 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
11/19/2021 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
11/19/2021 POS AM Form POS AM - Post-Effective amendments for registration statement:
11/19/2021 8-K Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Completion of Acquisition or Disp...
Docs: "AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF FLEXION THERAPEUTICS, INC.",
"BYLAWS OF FLEXION THERAPEUTICS, INC.",
"Supplemental Indenture”), between Flexion Therapeutics, Inc., a Delaware corporation , as issuer, and Wells Fargo Bank, National Association, a national banking association organized under the laws of the United States of America, as trustee , to the Indenture, dated as of May 2, 2017 (as supplemented or otherwise modified prior to the date hereof, the “Indenture"
11/19/2021 SC 14D9/A Form SC 14D9/A - Solicitation, recommendation statements: [Amend]
11/19/2021 SC TO-T/A Form SC TO-T/A - Tender offer statement by Third Party: [Amend]
11/19/2021 25-NSE Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities:
11/18/2021 SC 14D9/A Form SC 14D9/A - Solicitation, recommendation statements: [Amend]
11/18/2021 SC TO-T/A Form SC TO-T/A - Tender offer statement by Third Party: [Amend]
11/17/2021 SC 14D9/A Form SC 14D9/A - Solicitation, recommendation statements: [Amend]
11/12/2021 10-Q Quarterly Report for the period ended September 30, 2021
11/12/2021 SC TO-T/A Form SC TO-T/A - Tender offer statement by Third Party: [Amend]
11/09/2021 SC 13G/A WASATCH ADVISORS INC reports a 0% stake in Flexion Therapeutics Inc.
11/01/2021 SC 14D9/A Form SC 14D9/A - Solicitation, recommendation statements: [Amend]
11/01/2021 SC TO-T/A Form SC TO-T/A - Tender offer statement by Third Party: [Amend]
10/22/2021 SC 14D9 Form SC 14D9 - Solicitation, recommendation statements:
10/22/2021 SC TO-T Form SC TO-T - Tender offer statement by Third Party:
10/12/2021 SC14D9C Form SC14D9C - Written communication relating to third party tender offer:
10/12/2021 SC TO-C Form SC TO-C - Written communication relating to an issuer or third party:
10/12/2021 8-K Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Other Events, Financial Statements...
Docs: "AGREEMENT AND PLAN OF MERGER by and among: FLEXION THERAPEUTICS, INC., PACIRA BIOSCIENCES, INC., and OYSTER ACQUISITION COMPANY INC.",
"TENDER AND SUPPORT AGREEMENT This Tender and Support Agreement is entered into as of October 11, 2021, by and among Pacira BioSciences, Inc., a Delaware corporation , Oyster Acquisition Company Inc., a Delaware corporation and a wholly owned subsidiary of Parent , and [●] . Recitals A. Stockholder is a holder of record and the “beneficial owner” ) of certain shares of common stock of Flexion Therapeutics, Inc., a Delaware corporation . B. Parent, Purchaser and the Company are entering into an Agreement and Plan of Merger dated on or about the date hereof which provides, among other things, for Purchaser to commence a cash tender offer to acquire all of the outstanding shares of Company Common Stock, par value $0.001 per share, of the Company and following the consummation of the Offe...",
"Pacira BioSciences to Acquire Flexion Therapeutics Further Expanding Leadership Position in Non-Opioid Pain Management"
08/04/2021 10-Q Quarterly Report for the period ended June 30, 2021
08/04/2021 8-K Investor presentation, Quarterly results
Docs: "Flexion Therapeutics Reports Second-Quarter 2021 Financial Results and Recent Business Highlights  ZILRETTA® net sales were $28.2 million in Q2 2021, reflecting growth of 15% over the previous quarter  Net loss in Q2 2021 decreased by $10.4 million , as compared to Q2 2020, during the height of the COVID-19 impact on ZILRETTA sales  Company extends estimated cash runway into 2023 by refinancing term loan  Flexion reiterates full-year 2021 ZILRETTA net sales guidance in the range of $120 million to $130 million  Data for FX301 bunionectomy study and FX201 single ascending dose/expansion knee osteoarthritis study anticipated by year-end  Conference call to be held today at 4:30 pm",
"Q2 2021 Commercial Metrics Overview August 4, 2021 Exhibit 99.2"
07/12/2021 8-K Appointed a new director
06/25/2021 8-K Quarterly results
05/12/2021 10-Q Quarterly Report for the period ended March 31, 2021
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy